Northern Trust
QTTB icon

Northern Trust’s Q32 Bio QTTB Stock Holding History

Northern Trust’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$161K Hold
25,033
– – ﹤0.01% 4000
2025
Q4 		$83.1K Sell
25,033
-6,920
-22% -$19.6K ﹤0.01% 4171
2025
Q3 		$63.3K Buy
31,953
+5,895
+23% +$11.3K ﹤0.01% 4237
2025
Q2 		$38.8K Sell
26,058
-34,076
-57% -$58.1K ﹤0.01% 4273
2025
Q1 		$99.2K Sell
60,134
-53
-0.1% -$143 ﹤0.01% 4115
2024
Q4 		$207K Sell
60,187
-1,068
-2% -$33.7K ﹤0.01% 3980
2024
Q3 		$2.73M Buy
+61,255
New +$2.25M ﹤0.01% 2804
2024
Q1 		– Sell
-3,653
Closed -$40K – 4494
2023
Q4 		$40K Hold
3,653
– – ﹤0.01% 4272
2023
Q3 		$76.9K Sell
3,653
-33
-0.9% -$673 ﹤0.01% 4067
2023
Q2 		$58.7K Sell
3,686
-1,581
-30% -$28.4K ﹤0.01% 4179
2023
Q1 		$97.6K Buy
5,267
+28
+0.5% +$698 ﹤0.01% 4091
2022
Q4 		$119K Sell
5,239
-20
-0.4% -$531 ﹤0.01% 4039
2022
Q3 		$152K Buy
5,259
+65
+1% +$2.65K ﹤0.01% 3982
2022
Q2 		$184K Sell
5,194
-17,528
-77% -$598K ﹤0.01% 3971
2022
Q1 		$1.24M Sell
22,722
-967
-4% -$60.1K ﹤0.01% 3324
2021
Q4 		$1.55M Buy
23,689
+175
+0.7% +$17K ﹤0.01% 3350
2021
Q3 		$3.33M Sell
23,514
-1,202
-5% -$153K ﹤0.01% 2999
2021
Q2 		$3.23M Buy
24,716
+2,857
+13% +$357K ﹤0.01% 3107
2021
Q1 		$3.7M Sell
21,859
-2,329
-10% -$490K ﹤0.01% 2929
2020
Q4 		$4.92M Sell
24,188
-435
-2% -$84.1K ﹤0.01% 2691
2020
Q3 		$4.74M Sell
24,623
-856
-3% -$192K ﹤0.01% 2566
2020
Q2 		$6.97M Buy
25,479
+7,346
+41% +$1.96M ﹤0.01% 2317
2020
Q1 		$5.07M Buy
18,133
+354
+2% +$108K ﹤0.01% 2293
2019
Q4 		$6.62M Sell
17,779
-927
-5% -$265K ﹤0.01% 2419
2019
Q3 		$6.09M Buy
18,706
+4,456
+31% +$1.51M ﹤0.01% 2433
2019
Q2 		$5.02M Buy
14,250
+3,871
+37% +$1.52M ﹤0.01% 2563
2019
Q1 		$5.18M Buy
10,379
+303
+3% +$135K ﹤0.01% 2540
2018
Q4 		$4.05M Buy
10,076
+3,343
+50% +$1.26M ﹤0.01% 2633
2018
Q3 		$2.77M Buy
6,733
+590
+10% +$200K ﹤0.01% 3031
2018
Q2 		$2.25M Buy
+6,143
New +$2.2M ﹤0.01% 3143

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust's QTTB Position: Q1 2026 in Review

Northern Trust held its Q32 Bio (QTTB) position steady in Q1 2026 at 25,033 shares worth $161K. The position accounts for ﹤0.01% of the portfolio, ranked #4000.

Northern Trust first reported a position in QTTB in Q2 2018 and has held it in 30 quarters since. The position peaked at $6.97M in Q2 2020. 54 funds tracked by Wall St. Rank hold QTTB as of Q1 2026.

  • Northern Trust held 25,033 shares of Q32 Bio worth $161K as of Q1 2026.
  • Northern Trust left its Q32 Bio share count unchanged in Q1 2026.
  • Q32 Bio made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4000 holding.
  • Northern Trust first reported a position in Q32 Bio in Q2 2018 and has held it in 30 quarters since.
  • Northern Trust's Q32 Bio position peaked at $6.97M in Q2 2020.
  • 54 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.